Ticagrelor Tablet
Product Images NDC 67877-491

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 67877-491). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ticagrelor-90mg-60tabs (Ticagrelor 90mg 60s)

The image shows a Ticagrelor tablet label containing 90 mg of ticagrelor, labeled as a human prescription drug. The label includes the Ascend Laboratories, LLC logo and states a package size of 60 tablets. It features dosage and storage warnings, manufacturer Alkem Laboratories Ltd., Mumbai, India, and distributor Ascend Laboratories, LLC, Bedminster, NJ. There are two barcodes and specific printing instructions for the label's varnish area.*

FDA Label Image

Ticagrelor-debossing (Ticagrelor Debossing)

Ticagrelor 90 mg oral tablets packaging label from Ascend Laboratories, LLC. The label includes the proprietary and generic name Ticagrelor, the dosage strength of 90 mg, route of administration as oral, and the product NDC 67877-491. The label is straightforward, primarily text-based on a white background.*

FDA Label Image

Ticagrelor-fig001 (Ticagrelor Fig001)

A cumulative percentage line graph comparing Ticagrelor 90 mg and Clopidogrel over 360 days. The x-axis shows days from first study drug dose, and the y-axis shows cumulative percentage. Ticagrelor is represented by a solid line and Clopidogrel by a dashed line, with patient numbers at risk at various intervals indicated below the x-axis.*

FDA Label Image

Ticagrelor-fig002 (Ticagrelor Fig002)

A bar chart showing the percentage of patients who experienced an event following CABG surgery over multiple days. The x-axis represents days post-surgery, and the y-axis represents the percentage of patients. Two groups are compared, labeled "T" and "C," with corresponding numerical data below the chart indicating event counts and totals for each day.*

FDA Label Image

Ticagrelor-fig011 (Ticagrelor Fig011)

A forest plot comparing the hazard ratios (HR) with 95% confidence intervals (CI) between Ticagrelor and Clopidogrel across various patient characteristics and subgroups. The plot displays treatment effects for overall primary endpoint, geographic region, ASA dose, treatment approach, early PCI status, post-randomization CABG, diabetes history, prior TIA/stroke, Glycoprotein IIb/IIIa inhibitor use, age groups, sex, and race. Ticagrelor generally shows favorable HR values compared to Clopidogrel, indicated by points positioned left of the centerline.*

FDA Label Image

Ticagrelor-fig014 (Ticagrelor Fig014)

A forest plot displaying hazard ratios (HR) and 95% confidence intervals (CI) comparing Ticagrelor 90 mg tablets versus placebo across various patient characteristics and subgroups, including age, sex, race, weight, BMI, geographic region, medical history, and other clinical factors. The plot evaluates the relative treatment effect on the primary endpoint, with HR values indicating whether Ticagrelor or placebo is favored.*

FDA Label Image

Ticagrelor-fig09 (Ticagrelor Fig09)

A pharmacokinetic chart showing the mean effect and 90% confidence intervals for various interacting drugs with ticagrelor at different doses, depicting changes in Cmax and AUC relative to the interacting drug alone. Recommendations for dose adjustments, including maximum simvastatin dose, no dose adjustment for others, are listed on the right side.*

FDA Label Image

Ticagrelor-fig12 (Ticagrelor Fig12)

A forest plot comparing the efficacy outcomes of Ticagrelor versus Clopidogrel across US and Non-US regions with varying doses of ASA (Aspirin). The horizontal axis shows the hazard ratio (HR) and 95% confidence intervals (CI), where values below 1 favor Ticagrelor and above 1 favor Clopidogrel. The plot includes sample sizes and event counts for each subgroup.*

FDA Label Image

Fig-5 (Ticagrelor Fig5)

Line graph depicting IPA (%) induced by 20uM ADP over time (hours) for Ticagrelor 180 mg, Clopidogrel 600 mg, and placebo. The graph shows Ticagrelor reaching about 90% inhibition rapidly, Clopidogrel reaching about 50%, and placebo remaining below 15% over 8 hours with error bars.*

FDA Label Image

Ticagrelor-06 (Ticagrelor G06)

A line graph showing IPA (%) induced by 20μM ADP over time in days for Ticagrelor, Clopidogrel, and Placebo groups. Ticagrelor and Clopidogrel exhibit higher initial IPA levels that decline over 10 days, while Placebo remains near zero. An inset graph shows IPA (%) over hours up to 48, illustrating similar trends with Ticagrelor and Clopidogrel starting at higher IPA than Placebo.*

FDA Label Image

Ticagrelor-g07 (Ticagrelor G07)

A forest plot chart titled 'Mean Effect and 90% CI' comparing Ticagrelor and another compound, showing pharmacokinetic parameters (Cmax and AUC) across different intrinsic factors such as age, gender, ethnicity, renal impairment, end-stage renal disease on hemodialysis, and mild hepatic impairment. The chart includes recommendations of 'No dose adjustment' for all factors and depicts change relative to reference values on the x-axis.*

FDA Label Image

Fig-10 (Ticagrelor I 10)

A cumulative percentage line graph comparing event rates over 360 days from randomization between Ticagrelor 90 mg and Clopidogrel. The x-axis shows days from randomization, and the y-axis shows cumulative percentage. The graph includes patient numbers at risk for each group at several time points and statistical data (HR, p-value) in an inset.*

FDA Label Image

Ticagrelo-fig-08 (Ticagrelor I08)

A comparative chart displaying mean effects and 90% confidence intervals for ticagrelor and AR-C124910XX interacting with various drugs. The chart lists interacting drugs including ketoconazole, diltiazem, rifampin, aspirin, desmopressin, heparin, enoxaparin, cyclosporine, morphine, and fentanyl with corresponding recommendations such as avoiding concomitant use or dose adjustments. The pharmacokinetic parameters Cmax and AUC are represented by squares and triangles, respectively, plotted against change relative to reference on the x-axis.*

FDA Label Image

Ticagrlor-im013 (Ticagrelor M 13)

A cumulative percentage line graph showing patient event rates over days from randomization for Ticagrelor 90 mg, Ticagrelor 60 mg, and placebo groups. The y-axis indicates cumulative percent, and the x-axis shows time in days up to 1320. The graph includes event counts and hazard ratios with confidence intervals and p-values for comparisons between groups.*

FDA Label Image

Ticagrelor-struct (Ticagrelor Struct)

Chemical structure of Ticagrelor, showing its molecular framework with various functional groups including fluorinated aromatic, cyclopropyl, and hydroxyl groups attached to a nucleoside-like core.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.